StemCells (NASDAQ: STEM) reported Q2 EPS of ($0.09), in-line with the analyst estimate of ($0.09). Revenue for the quarter came in at $30 thousand versus the consensus estimate of $30 thousand.

"Our clinical programs achieved several key milestones since our last earnings release," reported StemCells CEO Martin McGlynn. "Based on the strength of the safety and preliminary efficacy data from our Phase I/II clinical studies, our Phase II proof-of-concept trials are now underway in two serious CNS disorders, each of which represents a large unmet medical need. Health Canada joined the FDA in authorizing our Phase II clinical trial in spinal cord injury and, having completed transplantation of the first cohort, we began enrolling the second cohort in this study. Enrollment in our Phase II clinical trial in geographic atrophy of age-related macular degeneration also commenced."

For earnings history and earnings-related data on StemCells (STEM) click here.